Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Samaritan signs research and licensing agreement with McGill University
August 2007
SHARING OPTIONS:

MONTREAL—Samaritan Pharmaceuticals Inc., and Samaritan Therapeutics, Canada, announce a research collaboration and licensing agreement with The Research Institute of McGill University Health Centre (RI-MUHC) in Montreal, to advance its promising pipeline into clinical trial status and develop new innovative drug candidates. During the initial phase of the agreement, RI-MUHC will continue the previous studies led by Dr. Vassilios Papadopoulos, at Georgetown University, who is now the director of The RI-MUHC. Under the Samaritan agreement, RI-MUHC will continue to develop the drug pipeline which was originally developed in the Georgetown University/Samaritan collaboration, and in addition, take potential new drug candidates through the discovery process.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.